Dapoxetine 30mg Tablet

◦ Persistent or recurrent ejaculation within approximately 1 minute of vaginal penetration (confirmed by stopwatch-measured IELT ≤60 seconds at baseline) ◦ Persistent or recurrent ejaculation within approximately 1 minute of vaginal penetration (confirmed by stopwatch-measured IELT ≤60 seconds at baseline) ◦ Inability to delay ejaculation during all or nearly all vaginal penetrations ◦ Inability to delay ejaculation during all or nearly all vaginal penetrations ◦ Negative personal consequences (distress, frustration, avoidance of sexual intimacy) ◦ Negative personal consequences (distress, frustration, avoidance of sexual intimacy) Premature Ejaculation Diagnostic Tool (PEDT) score ≥11. Premature Ejaculation Diagnostic Tool (PEDT) score ≥11.

Reviews (0)

Initially developed for depression, SSRIs such as citalopram were repurposed for PE after clinical observations revealed their ejaculatory delay as a side effect [7]. Randomized trials demonstrated that daily citalopram significantly prolonged IELT and improved patient satisfaction and ejaculatory control [8]. To address the need for on-demand therapy, dapoxetine, a short-acting SSRI, was specifically developed and became the first drug approved for PE in several countries. Clinical trials confirmed its efficacy in significantly increasing IELT and improving sexual satisfaction when taken before intercourse. While daily SSRIs demonstrated efficacy in PE treatment, their requirement for continuous administration and delayed onset (2–3 weeks) created demand for an on-demand alternative [9]. In a stable, monogamous, heterosexual relationship for at least 3 months.

Statistical analysis

The findings suggest that citalopram is a highly effective first-line option, while the dose-dependent efficacy of dapoxetine and the distinct side-effect profile of silodosin provide alternative considerations for personalized treatment strategies. This clinical trial was registered at ClinicalTrials.gov (Identifier NCT07113145) on 7 August 2025 after the enrollment of the first participant and is therefore retrospectively registered.” Premature ejaculation (PE) is a common male sexual complaint, with an estimated global prevalence of 20–30% [1,2,3]. Although diagnostic criteria vary, approximately 1–3% of men experience severe forms characterized by an intravaginal ejaculatory latency time (IELT) of one minute or less [4]. PE is associated with significant psychological distress, reduced sexual satisfaction, impaired self-confidence, and a negative impact on the quality of life of both patients and their partners [5]. Over the years, treatment strategies for PE have evolved from behavioral and topical interventions to pharmacological approaches, primarily involving selective serotonin reuptake inhibitors (SSRIs) [6]. Signed informed consent indicating willingness to participate. Use of PE medications in the preceding 4 weeks. Patients with erectile dysfunction through medical history. History of psychiatric or significant physical disorders (in either patient or partner). Use of antidepressants, local anesthetic sprays, intracavernosal injections, or psychotherapy within 4 weeks. Participants were randomly assigned to four equal groups (n = 100 each) using a computer-generated and centralized randomization: Group A: Received Citalopram hydrobromide, starting with 10 mg once daily for 1 week, followed by 20 mg once daily for 10 weeks, and 10 mg daily during the final week (tapered). Group A: Received Citalopram hydrobromide, starting with 10 mg once daily for 1 week, followed by 20 mg once daily for 10 weeks, and 10 mg daily during the final week (tapered). Group B: Received Silodosin 4 mg, administered orally once daily. Group C: Received Dapoxetine hydrochloride 30 mg, taken 2 h before intercourse, on-demand, minimum of 8 times/month for 3 months. Group D: Received Dapoxetine hydrochloride 30 mg, administered daily.

Poxet 60 mg Dapoxetine Tablets (Priligy)

Another agent, silodosin, a selective α1A-adrenoceptor antagonist originally approved for lower urinary tract symptoms, emerged as a potential PE therapy due to its common side effect of ejaculatory dysfunction. Early studies demonstrated that silodosin could substantially prolong IELT in men with PE, making it a promising off-label option [10, 11]. Given the fact that there was no previous study addressing the comparison of the three drugs together and the limitations with varying mechanisms of existing therapies, this randomized clinical trial was designed to evaluate and compare the efficacy and safety of Citalopram, Silodosin 4 mg, Dapoxetine 30 mg (on demand), and Dapoxetine 30 mg (daily) in the treatment of PE. This randomized clinical study was conducted between June 2024 and March 2025. A total of 400 male patients diagnosed with PE were enrolled. Comprehensive medical history, including comorbidities (e.g., diabetes, hypertension), medication review for drug interactions, erectile function and prostatitis. Physical examination focused on genitourinary abnormalities (e.g., prostatitis, hypospadias). Lab tests: including FSH, LH, free testosterone, cholesterol, and triglycerides. The assessors of the outcomes were blinded during the study procedures. Adherence was assessed at each visit by pill count and patient diaries. We assessed clinical meaningfulness using distribution-based MCID thresholds because there is currently no published literature which identifies a clinically significant threshold response to IVELT and PEPQ.

What Is Priligy and Why Does It Matter?

All four treatment groups demonstrated significant within-group improvements in IELT from baseline (p < 0.001 for all). The citalopram group exhibited the greatest mean IELT increase (from 110.4 ± 31.5s to 391.2 ± 45.9s; 260% median gain), outperforming the daily dapoxetine (220%), on-demand dapoxetine (197%), and silodosin (149.5%) groups. Improvements in PEPQ scores mirrored the IELT findings, with citalopram showing a 300% improvement compared to 225%, 166.7%, and 175% in the daily dapoxetine, on-demand dapoxetine, and silodosin groups, respectively. Adverse event profiles differed: silodosin was associated with a higher incidence of ejaculatory dysfunction (23% retrograde ejaculation), while daily dapoxetine led to more systemic effects (18% dizziness). In this direct head-to-head comparison of active treatments for lifelong PE, daily citalopram (20 mg) demonstrated superior efficacy in prolonging IELT and improving psychosocial outcomes compared to daily or on-demand dapoxetine and silodosin. Following established methodology, we prespecified 0.5 SD of baseline IVELT and PEPQ as the primary MCID. Intravaginal Ejaculatory Latency Time (IELT): Measured by the partner using a wristwatch (Casio®, Tokyo, Japan), defined as the interval between vaginal penetration and ejaculation. IELT was recorded pre- and post-intervention (after 3 months). Premature Ejaculation Profile Questionnaire (PEPQ) [13]: Evaluated perceived ejaculatory control, sexual satisfaction, personal distress, and interpersonal difficulty.

ED Treatment Medication

With 400 total participants (100 per group), the denominator df was 392, yielding a noncentrality parameter (λ) of 25.00 and achieving the target power of 0.950. This approach ensured adequate power to detect clinically meaningful differences while controlling relevant covariates. The total sample size in the ANOVA/ANCOVA framework was determined using the noncentral F distribution according to the following relationship: The achieved power is then calculated as: Using f = 0.25, α = 0.05, and 95% power, with four treatment groups and four covariates, the required sample size was confirmed as 400 participants (100 per group). Diagnosis of PE according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-V-TR) [12]. ◦ Persistent or recurrent ejaculation within approximately 1 minute of vaginal penetration (confirmed by stopwatch-measured IELT ≤60 seconds at baseline) ◦ Inability to delay ejaculation during all or nearly all vaginal penetrations ◦ Negative personal consequences (distress, frustration, avoidance of sexual intimacy) Premature Ejaculation Diagnostic Tool (PEDT) score ≥11. Each domain was assessed via a single-item, 5-point Likert scale (0–4), with higher scores indicating improved functioning. Side effects: Adverse effects were evaluated in terms of occurrence of nausea, diarrhea, vomiting, headaches, decreased semen volume, retrograde ejaculation, anejaculation, constipation, dizziness, sleep disturbance, and dry mouth. Statistical analysis was performed using SPSS version 26.0 (IBM Corp., Armonk, NY, USA). Continuous variables were expressed as mean ± SD; categorical variables as number and percentage. Between-group comparisons were analyzed using ANOVA with post-hoc Tukey tests. Within-group pre/post comparisons were analyzed using paired t-tests.

Why choose Hi-Doctor over unregulated peptide sellers

The study protocol was approved by the Institutional Review Board (IRB) of the Faculty of Medicine, Beni-Suef University (Approval No. : FMBSUREC/07052024/Ahmed), and all participants provided written informed consent prior to enrollment. A priori power analysis was conducted using G*Power 3.1 to determine the appropriate sample size for detecting differences in IELT among the four treatment groups. Based on an ANOVA model accounting for four treatment groups and four covariates (age, baseline IELT, comorbidities, and medication adherence), we calculated the required sample size using a medium effect size (f = 0.25), α = 0.05, and 95% power. The numerator degrees of freedom (df = 7) comprised 3 df for between-group comparisons (4 groups − 1) plus 4 df for the covariates. Categorical variables were compared using χ² or Fisher’s exact test. Significance was set at p < 0.05. A total of 400 participants were included. Figure 1 shows the CONSORT flow diagram of the study procedures (Table 1), show Baseline characteristics were comparable across the four groups, with no statistically significant differences in age, duration of the disorder, comorbidities (diabetes mellitus, hypertension, cardiac or hepatic/renal disease), or laboratory data including FSH, LH, free testosterone, cholesterol, and triglycerides.